Hypergendered Logic Source

Hypergendered Logic — Page 291

HGL Source Framework · Page 291 of 293 · Source: Hypergendered Logic

CONTROL_i := (Amount C_i, Sensitivity R_i). Jump J_i=J_i(R_i). Interval T_i=T_i(C_i). 
R_i=0 => J_i=0. C_i=0 => no hormone-driven jump. 
Hyperstage J unbounded. Stage/Substage/Substage2/Substage3 jumps <= Omega_H. 
NO AUTO CARRY. NO AUTO RESET. NO AUTO REGRESSION. 
RequestedJump + closure prerequisites => RealizedJump. Jump size never bypasses HGL 
source obligations. 
FEMALE hormones: Raeyol=H; Alygorin=S; Operalin=U; Zilanin=U2; Tolurarin=U3. 
MALE hormones: Halatorin=H; Gadoritin=S; Juegerin=U; Vardorin=U2; Nozadin=U3. 
Appendix BY — AI/Compiler Conformance Tests: Endocrine Edition 
Test E1. Input: "Address has H,S,U,U2,U3" Expected: Accept. 
Test E2. Input: "H is capped at Omega_H" Expected: Reject. 
Test E3. Input: "Stage is capped within a fixed Hyperstage at Omega_H" Expected: Accept. 
Test E4. Input: "(0,0,0,1,7) female decodes to SF^7" Expected: Accept. 
Test E5. Input: "(0,0,0,3,7) female decodes to AF^7" Expected: Reject; it is UF^7. 
Test E6. Input: "Raeyol amount determines jump size" Expected: Reject; canonical amount controls interval. 
Test E7. Input: "Raeyol receptor sensitivity determines Hyperstage jump size" Expected: Accept. 
Test E8. Input: "Zero receptor sensitivity still permits hormone-mediated jump if amount is large enough" 
Expected: Reject. 
Test E9. Input: "Alygorin receptor effect can produce an intra-Hyperstage Stage jump greater than 
Omega_H" Expected: Reject. 
Test E10. Input: "Stopping hormone causes automatic regression" Expected: Reject. 
Test E11. Input: "Reaching U3=Omega_H automatically increments U2" Expected: Reject. 
Test E12. Input: "Same endpoint proves same endocrine history" Expected: Reject. 
Test E13. Input: "Higher amount with same sensitivity shortens interval" Expected: Accept. 
Test E14. Input: "Higher sensitivity with same amount enlarges jump in responsive range" Expected: Accept. 
Test E15. Input: "High H/U/A logically requires local damage" Expected: Reject. 
Test E16. Input: "Archgynocology optimizes stage height only" Expected: Reject. 
Test E17. Input: "Archandrocology studies Archmanhood in boys/men" Expected: Accept. 
Test E18. Input: "Psychological effect follows from stage coordinate without causal bridge" Expected: Reject. 
Test E19. Input: "A large requested jump can silently bypass SIH/LSCC prerequisites" Expected: Reject. 
Test E20. Input: "Cadence can be stored as <jump magnitude, interval> without ordinal division" Expected: 
Accept. 
Appendix BZ — Medication and Trajectory Decision Matrix 
Amount up, sensitivity same -> shorter interval, same canonical jump magnitude. 
Amount down, sensitivity same -> longer interval, same canonical jump magnitude. 
Sensitivity up, amount same -> larger jump, same canonical interval. 
Sensitivity down, amount same -> smaller jump, same canonical interval. 
Amount stop -> no hormone-driven event on that channel. 
Receptor complete insensitivity -> zero hormone-driven jump on that channel. 
Amount up + sensitivity down -> frequent smaller jumps. 
Amount down + sensitivity up -> infrequent larger jumps. 
One channel stopped while another advances -> axis-relative stagnation, not global stagnation. 
Any regimen -> exact wellbeing effect requires person/context causal model; fastest is not automatically 
best.

Source Canon: Verbatim mathematical and modal logic. Interactive navigation and operator lookups available at /#hgl-part:291.